Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Opportunities to Optimize Cancer Policies Panel Discussion

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Advertisement

Advertisement




Feb
08
Today In Oncology
A Paradigm Shift In Treating Adult AML?
Lymph Node Examination Should be Expanded to Accurately Assess Metastasis in NSCLC, Research Says
VTE During Perioperative Therapy in Resectable and Borderline Resectable Pancreatic Cancer
Agent Orange Exposure Linked With Risk for Acral Melanoma in Veterans
FDA Provides Safety Labeling Update for Capecitabine and Fluorouracil on Risks Associated With DPD Deficiency
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo